Company intelligence / Profile preview

Jolly

San Francisco, California, United States

Ownership: Public · JOLYPLS
Employees: ~10
Development stage: Other

Overview

Jolly is a pre-clinical stage biotechnology company dedicated to discovering and developing medicines that rejuvenate cells to combat age-related decline. The company utilizes a proprietary high-throughput platform that integrates machine learning with advanced biological screening to identify novel rejuvenation factors. By focusing on epigenetic reprogramming, Jolly aims to reverse cellular aging and restore youthful function across various tissues. The startup's mission is to significantly extend human healthspan by addressing the root causes of aging. Founded by Ben Kamens, Jolly is positioned at the intersection of computational biology and regenerative medicine.

Therapeutic areas: Other
Modalities: Small moleculeGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Jolly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jolly.

Explore the full profile